San Francisco, US-based biotech BlackThorn Therapeutics has appointed Gregory Vontz as its new chief executive officer.
Vontz brings over 30 years of biotech and pharma industry experience to the role, joining from fungal infection specialist Tropica Pharmaceuticals where he also served as chief executive.
Prior to this, Vontz was president and chief operating officer of Connetics Corporation, spent 12 years in a series of senior marketing and product development roles at Genentech, and worked in sales and sales management at Merck & Co.
Dr Mark Corrigan, chairman of the board at BlackThorn, said: “On behalf of the Board and the BlackThorn team, I am pleased to welcome Greg as our new chief executive officer.
“His experience as a biotech executive, record of successful drug development and strategic transactions will serve BlackThorn well in advancing the company’s mission to develop new treatments for patients suffering from neurobehavioral disorders.”